Skip to main content

Table 3 The stroke rate (% of target population) across the datasets

From: Feasibility and evaluation of a large-scale external validation approach for patient-level prediction in an international data network: validation of models predicting stroke in female patients newly diagnosed with atrial fibrillation

 

Outcome rate % (Target population size)

Target Population

CCAE

MDCD

MDCR

Optum claims

Optum EHR

CUMC

AUSOM

STRIDE

T1: Females aged 65+ with atrial fibrillation no prior stroke or anticoagulants

4.95 (25,880)

4.40 (89,156)

4.07 (110,905)

1.30 (149,906)

5.75 (4312)

2.61 (268)

1.37 (3366)

T2: Females with atrial fibrillation no prior stroke or anticoagulants

1.33 (61,224)

4.61 (33,262)

3.49 (139,376)

1.13 (189,815)

5.00 (5758)

1.76 (455)

1.28 (4456)

Sensitivity T1: Females aged 65+ with atrial fibrillation no prior stroke or anticoagulants (no anticoagulants during tar)

5.04 (23,586)

5.26 (56,511)

4.48 (78,353)

1.44 (99,212)

6.23 (3403)

4.17 (144)

1.29 (2094)

Sensitivity T2: Females with atrial fibrillation no prior stroke or anticoagulants (no anticoagulants during tar)

1.28 (46,054)

4.69 (29,546)

3.73 (100,757)

1.22 (128,409)

5.35 (4546)

2.73 (256)

1.22 (2786)

  1. Target population size in each dataset and the percentage of patients with stroke within 1 year of initial atrial fibrillation diagnosis